Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by...
Hence then, the article about boostimmune secures japanese patent for sequence independent tctp antibody technology targeting mdsc accumulation was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation )
Also on site :
- One Minnesota Vikings Rookie Who Could Win a Starting Job Out of Camp
- Sheikh Hamad: The Arab leader who broke Israel’s siege on Gaza
- Paramount Reportedly Considering Leaving California as State Readies Lawsuit Over Warner Bros. Discovery Merger